Want to see TSE:BCT full AI Analyst Report?
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$3.68 - C$41.80
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$37.84M
Enterprise Value-C$1.60M
Total Cash (Recent Filing)C$22.80M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding8,699,787
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Net-cash Balance Sheet / No Reported DebtA net-cash position with no reported debt materially reduces near-term solvency risk for a pre-revenue biotech. This structural strength gives management more optionality on financing timing and partnership negotiations, improving resilience over the coming 2-6 months.
Focused Clinical-stage Immunotherapy Pipeline (Bria-IMT)A clear scientific focus on cell- and immune-based therapies, led by Bria-IMT and combination strategies, creates durable strategic optionality. Clinical-stage assets can drive long-term value via trial readouts, licensing or partnerships rather than short-term market moves.
Controlled Loss Trajectory Versus Prior PeriodsLosses remain large but have not meaningfully accelerated year-over-year, indicating some control over operating burn. For planning and financing, a relatively stable loss trend improves predictability of cash needs and reduces risk of sudden funding crises in the medium term.
Bears Say
Pre-revenue Business ModelWith no product revenue, the company’s economics depend entirely on clinical progress and external financing. That structural exposure magnifies execution and trial risk: failed readouts or delays directly impact funding ability and long-term viability absent revenue diversification.
High And Worsening Cash BurnElevated and increasing cash burn creates persistent financing needs and raises dilution risk. Over a 2-6 month horizon, worsening cash outflows tighten runway assumptions and force fundraising or partnership choices that can alter strategy or ownership structure.
Negative Returns And Equity VolatilityDeeply negative ROE and prior episodes of negative equity signal accumulated deficits and recurring financing interventions. This structural capital instability increases execution risk and potential for dilutive financings, complicating long-term strategic planning.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$3.68 and its highest was C$41.80 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$37.84M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 114 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Jun 09, 2026. The company reported -C$1.354 earnings per share for the quarter, missing the consensus estimate of N/A by -C$1.354.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 8,699,787 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$1.354 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.728%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-221.75%
Trailing 12-Months
Asset Growth
235.47%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---